Baselga, J., Morales, S. M., Awada, A., Blum, J. L., Tan, A. R., Ewertz, M., . . . Rugo, H. S. (2017). A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Res Treat.
Chicago ZitierstilBaselga, José, et al. "A Phase II Study of Combined Ridaforolimus and Dalotuzumab Compared With Exemestane in Patients With Estrogen Receptor-positive Breast Cancer." Breast Cancer Res Treat 2017.
MLA ZitierstilBaselga, José, et al. "A Phase II Study of Combined Ridaforolimus and Dalotuzumab Compared With Exemestane in Patients With Estrogen Receptor-positive Breast Cancer." Breast Cancer Res Treat 2017.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.